Curated News
By: NewsRamp Editorial Staff
September 18, 2025
Quantum BioPharma's Qlarity Gains Health Canada Approval for Canadian Market
TLDR
- Quantum BioPharma gains a competitive edge with Health Canada's Qlarity license, expanding market reach and potential revenue from Canadian sales.
- Health Canada granted Quantum BioPharma a product license for Qlarity, permitting its sale with specified uses based on regulatory approval processes.
- Qlarity's approval supports public health by aiding energy, cognition, and fatigue reduction, contributing to improved daily wellness in Canada.
- Quantum BioPharma's Qlarity, now licensed in Canada, offers a natural boost for mental alertness and endurance, building on its U.S. counterpart unbuzzd.
Impact - Why it Matters
This regulatory approval matters because it represents Quantum BioPharma's successful expansion into the Canadian health market, potentially making Qlarity accessible to millions of Canadians seeking natural solutions for energy, cognitive function, and fatigue. For investors, it demonstrates the company's ability to navigate complex regulatory pathways and execute on its commercialization strategy. The approval could drive revenue growth through direct sales and royalty streams from Unbuzzd Wellness, while also validating the company's scientific approach to natural health products. In the broader healthcare landscape, this adds another evidence-based option for consumers looking for natural alternatives to support mental and physical performance, particularly relevant as demand for cognitive enhancement and energy support products continues to grow in aging populations and high-stress modern lifestyles.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM, CSE: QNTM), a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders and alcohol misuse, has achieved a significant regulatory milestone with Health Canada granting a Product License (PN 80144141) for its natural health product Qlarity. This license authorizes the sale of Qlarity in Canada, with recommended uses including supporting energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance, and fatigue reduction. The company previously licensed a similar product in the United States under the brand name unbuzzd™, demonstrating its strategic expansion into North American markets.
Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is advancing its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, targeting the underlying mechanism of multiple sclerosis. The company maintains a diverse portfolio including its 20.11% ownership stake in Unbuzzd Wellness Inc., which markets the OTC version of unbuzzd™, with Quantum receiving royalty payments of 7% of sales until reaching $250 million, then 3% in perpetuity. Quantum retains full rights to develop similar products for pharmaceutical and medical applications, positioning itself across both consumer health and prescription drug markets.
For investors seeking the latest updates, the company's newsroom at the InvestorBrandNetwork provides comprehensive coverage of Quantum BioPharma's developments. This regulatory approval represents a crucial step in Quantum's commercial strategy, expanding its market reach and validating its product development capabilities in the competitive biopharmaceutical landscape.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Qlarity Gains Health Canada Approval for Canadian Market
